Russell Investments Group Ltd. Cuts Position in Omnicell, Inc. $OMCL

Key Points

• Russell Investments Group Ltd. reduced its stock position in Omnicell, Inc. by 17.7%, ending with approximately 86,462 shares valued at $3,023,000.
• Omnicell reported a net revenue increase of 5.0% year-over-year, with earnings per share of $0.45, which exceeded analysts' estimates of $0.30.
• Research analysts have a consensus rating of "Moderate Buy" for Omnicell, with a price target averaging $46.71 despite recent adjustments from several firms.

Russell Investments Group Ltd. cut its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 17.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 86,462 shares of the company's stock after selling 18,635 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.18% of Omnicell worth $3,023,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Johnson Financial Group Inc. acquired a new position in shares of Omnicell during the fourth quarter worth about $37,000. Point72 Hong Kong Ltd acquired a new position in shares of Omnicell during the fourth quarter worth about $101,000. Corton Capital Inc. acquired a new position in shares of Omnicell during the fourth quarter worth about $208,000. Caption Management LLC acquired a new position in shares of Omnicell during the fourth quarter worth about $223,000. Finally, Occudo Quantitative Strategies LP acquired a new position in shares of Omnicell during the fourth quarter worth about $286,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on OMCL shares. Bank of America boosted their target price on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Benchmark decreased their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Wells Fargo & Company boosted their target price on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Piper Sandler decreased their target price on Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Finally, Wall Street Zen cut Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $46.71.

Omnicell Stock Performance

Shares of NASDAQ:OMCL traded up $0.05 during trading on Thursday, reaching $33.28. The company had a trading volume of 347,117 shares, compared to its average volume of 568,363. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of 66.56, a price-to-earnings-growth ratio of 7.15 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The stock's fifty day moving average price is $29.88 and its 200 day moving average price is $31.75. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The company's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, equities research analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.